RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipientsJohn D. Isaacs, Rafael Henkin, Philip Stocks et al.|Scientific Data|2022Cited by 25
1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)Jonathan W. Riess, Ezra E.W. Cohen, James Spicer et al.|Annals of Oncology|2023Cited by 2
756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)Jonathan W. Riess, Pilar Garrido, James Spicer et al.|Regular and Young Investigator Award Abstracts|2024Cited by 1